Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/Phase 2, Randomized, Open-label, Multi Cohort, Multi Center, Study Assessing the Safety, Tolerability and Preliminary Efficacy of SAR443579 a Natural Killer Cell Engager (NKCE) Targeting CD123, Administered With Different Agents in Participants With CD123 Expressing Hematological Malignancies

Trial Profile

A Phase 1/Phase 2, Randomized, Open-label, Multi Cohort, Multi Center, Study Assessing the Safety, Tolerability and Preliminary Efficacy of SAR443579 a Natural Killer Cell Engager (NKCE) Targeting CD123, Administered With Different Agents in Participants With CD123 Expressing Hematological Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; IPH 6101 (Primary) ; Venetoclax (Primary)
  • Indications Acute-Megakaryocytic-Leukemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi

Most Recent Events

  • 10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition
  • 03 Dec 2024 According to Innate Pharma media release, data from the study will be presented at American Society of hematology (ASH) Annual Meeting.
  • 28 Nov 2024 Planned End Date changed from 12 Feb 2029 to 13 Aug 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top